Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH
Top

01-10-2019 | Renal cell carcinoma | Video | Article

Researcher comment: JAVELIN Renal 101 – Combination approach for advanced RCC patients without upfront cytoreductive nephrectomy

print
PRINT
insite
SEARCH

Laurence Albiges discusses a JAVELIN Renal 101 subgroup analysis indicating that avelumab plus axitinib achieves tumor reduction in patients with metastatic renal cell carcinoma (2:30).

External Content

Click Play to display this content and agree to third party cookies. (>)

Update your current cookie settings.

Read the transcript


This independent video interview was supported by an educational grant from Pfizer and Merck KGaA.

print
PRINT
  • » This content is intended only for healthcare providers and was made possible by educational funding provided by F. Hoffmann-La Roche Ltd.

Related content

08-10-2019 | Renal cell carcinoma | Conference coverage | News

JAVELIN Renal 101 subanalyses add to evidence for avelumab plus axitinib

30-09-2019 | Renal cell carcinoma | Video | Article

Expert comment: RCC immunotherapy – biomarker round-up

04-10-2019 | Renal cell carcinoma | Video | Article

Expert highlights: RCC immunotherapy at ESMO 2019

30-10-2018 | Renal cell carcinoma | ESMO 2018 | Video

Expert comment on the JAVELIN Renal 101 trial
Image Credits